NCT Number: NCT00087737
Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder
To compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with MDD.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Outpatients.
- Sexually active individuals participating in the study must use a medically acceptable form of contraception during the study and for at least 15 days after the last dose of test article
- Subjects must have a primary diagnosis of major depressive disorder
Exclusion criteria
- Treatment with DVS-233 SR at any time in the past
- Treatment with venlafaxine (immediate release [IR] or ER) within 90 days of study day 1
- Known hypersensitivity to venlafaxine (IR or ER)
Treatment and study plan
Venlafaxine ER
DrugInterested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder
Important dates
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Jul 16, 2004
- Registry last updated
- Aug 19, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
NCT05376150
Behavior, Behavioral Symptoms
Anaheim, California, United States
View Trial DetailsIndividualized dlPFC-NAcc Modulation for Anhedonia in adMDD
NCT05544071
Depressive Disorder, Depressive Disorder, Major
Xi'an, Shaanxi, China
View Trial DetailsA Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD
NCT06236880
Depressive Disorder, Depressive Disorder, Major
Manchester, United Kingdom
View Trial DetailsHyperthermic Yoga for Depressive Symptoms
NCT02607514
Behavior, Behavioral Symptoms
Boston, Massachusetts, United States
View Trial Details